Don’t Call it AI if it isn’t

In biotech, “AI” has officially joined the ranks of overused buzzwords – right up there with “platform” and “transformative.” And here’s the thing: if you’re using the label without meaningful substance – Are you adding real value or raising red flags? 

At Liberi, we talk to investors and BD leaders across the globe, and the message is clear: AI is no longer impressive by default. If your deck mentions machine learning or neural networks but your product is a glorified dashboard, you’re not differentiating – you’re diluting.

Tip for biotech founders: unless your AI is actively driving discovery, stratifying patients, predicting outcomes, or enabling a novel therapeutic angle, leave the label out.

Investors are asking sharper questions. Pharma scouts have seen hundreds of “AI drug discovery” decks. You won’t stand out by using the term – you’ll stand out by showing real impact.

So here’s the rule:

• Don’t sell it as AI unless you can show why it matters.
• If you can’t explain your model architecture, training data, or validation metrics in a way that supports your science –  don’t call it AI.

It’s not that AI isn’t powerful. It is. But misusing the label makes you less credible, not more attractive.

Save the buzz. Show the value.

The Liberi Team